Equity Overview
Price & Market Data
Price: $21.58
Daily Change: +$0.285 / 1.32%
Daily Range: $20.88 - $21.69
Market Cap: $307,704,832
Daily Volume: 28,027
Performance Metrics
1 Week: -1.84%
1 Month: 0.52%
3 Months: 54.18%
6 Months: -0.74%
1 Year: -41.93%
YTD: -6.52%
Company Details
Employees: 107
Sector: Health technology
Industry: Biotechnology
Country:
Details
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreements with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.